Fig. 7.
Dual-crosslinked hydrogel (SP@PRP gel, SP@PRP-Exos, and SP@MSC-Exos) treatment-inhibited inflammatory response, induced angiogenesis, and enhanced cell proliferation at diabetic wound sites on days 7 and 14. (A) Immunofluorescence detection of MPO and CD206-positive cells. (B) Immunohistochemical detection of CD31 and Ki67-positive cells. (C) Statistical analysis of MPO-positive cells (n = 3). (D) Statistical analysis of CD206-positive cells (n = 3). (E) Statistical analysis of CD31-microvessels (n = 3). (F) Statistical analysis of Ki67-positive cells (n = 3). *P < 0.05, **P < 0.01.